Urinary C-type natriuretic peptide: An emerging biomarker for heart failure and renal remodeling

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.

Original languageEnglish (US)
Pages (from-to)108-113
Number of pages6
JournalClinica Chimica Acta
Volume443
DOIs
StatePublished - Mar 1 2015

Fingerprint

C-Type Natriuretic Peptide
Biomarkers
Heart Failure
Kidney
Cardio-Renal Syndrome
Chronic Renal Insufficiency
Cell proliferation
Public health
Intercellular Signaling Peptides and Proteins
Hospitalization
Fibrosis
Public Health
Economics
Cell Proliferation
Hormones
Cytokines
Mortality

Keywords

  • Biomarker
  • C-type natriuretic peptide
  • Cardiorenal syndrome
  • Heart failure
  • Renal remodeling

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Urinary C-type natriuretic peptide : An emerging biomarker for heart failure and renal remodeling. / Zakeri, Rosita; Burnett, John C Jr.; Sangaralingham, S Jeson.

In: Clinica Chimica Acta, Vol. 443, 01.03.2015, p. 108-113.

Research output: Contribution to journalArticle

@article{b32e7844b5fc4e16b4cbc6837616307f,
title = "Urinary C-type natriuretic peptide: An emerging biomarker for heart failure and renal remodeling",
abstract = "The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.",
keywords = "Biomarker, C-type natriuretic peptide, Cardiorenal syndrome, Heart failure, Renal remodeling",
author = "Rosita Zakeri and Burnett, {John C Jr.} and Sangaralingham, {S Jeson}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.cca.2014.12.009",
language = "English (US)",
volume = "443",
pages = "108--113",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Urinary C-type natriuretic peptide

T2 - An emerging biomarker for heart failure and renal remodeling

AU - Zakeri, Rosita

AU - Burnett, John C Jr.

AU - Sangaralingham, S Jeson

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.

AB - The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.

KW - Biomarker

KW - C-type natriuretic peptide

KW - Cardiorenal syndrome

KW - Heart failure

KW - Renal remodeling

UR - http://www.scopus.com/inward/record.url?scp=84924260095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924260095&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.12.009

DO - 10.1016/j.cca.2014.12.009

M3 - Article

C2 - 25512164

AN - SCOPUS:84924260095

VL - 443

SP - 108

EP - 113

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -